How QbD Improves Regulatory Outcomes in Stability Submissions
Pharmaceutical regulatory agencies expect robust, science-based justifications for all aspects of a product’s lifecycle, especially in stability testing. By integrating Quality by Design (QbD) principles, companies can dramatically improve the quality, reliability, and acceptability of stability data included in regulatory filings. This article explores how QbD influences regulatory outcomes, drawing from ICH guidelines, FDA expectations,…
Read More “How QbD Improves Regulatory Outcomes in Stability Submissions” »